The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Embattled CytoDyn and key ex-executives must face an investor lawsuit claiming the company knowingly misled shareholders ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the ...

Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 ...

Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile ...

The FDA is amplifying a recall from Medtronic for its acid reflux testing system, after the company said it received 33 ...

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection against COVID-19 than available vaccines. | Invivyd has touted its ...